CompugenCGEN
Recorded

Compugen Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Steven WilleySenior Biotech Analyst

All right. We're going to go ahead and get started. I'm Stephen Willey, one of the Senior Biotech Analysts here at Stifel, and glad to have with us to wrap up the morning session, Eran Ophir, who is the CEO of Compugen. Eran, thanks for joining us. I actually ran into Anat at ESMO.

Steven WilleySenior Biotech Analyst

Oh, really? I hadn't seen her in a while.

Eran OphirCEO

Okay. She's still involved? Yeah.

Steven WilleySenior Biotech Analyst

She's still chair of the board, right?

Steven WilleySenior Biotech Analyst

Absolutely. Okay. Any opening statements you want to make before we jump into Q&A?

Eran OphirCEO

Yeah. Maybe for those who are new to the story, you can say a few sentences about Compugen. Compugen is relying on our computational AI-based engine that we built for years to identify new drug targets in the field of immuno-oncology, and we're pursuing these targets clinically through internal pipeline and also through collaborations. The engine is, if you may, validated because we have shown we can identify computationally drug targets, take them to the clinic, collaborate with pharma. Internally, we have the COM701 molecule, which is an anti-PVRIG antibody, which is now in a randomized study, the MAIA-ovarian trial, in a maintenance settings for platinum-sensitive ovarian cancer. We have two ongoing collaborations, one with AstraZeneca on the molecule rilvegostomig. The TIGIT arm of that bispecific PD1-TIGIT antibody is actually our own COM902, derived from our own COM902.

Eran OphirCEO

This interesting molecule is now in 12 phase III studies. We have another collaboration ongoing with Gilead on another first-in-class program that we identified computationally. Altogether, we have more than $1 billion in milestones and royalties from these collaborations. Behind all of that, we continue to use Unigen, recently announced the expansion into UnigenX for identifying targets also for T-cell engagers. This goes into the early pipeline. We have a solid cash balance with cash runway into 2029, allowing us to progress all our programs, so to get into catalysts in 2027, 2028.

Steven WilleySenior Biotech Analyst

Okay, perfect. Maybe we can start with MAIA-ovarian. I think you announced yesterday you completed enrollment into the trial. This is a kind of adaptive platform-type study that is evaluating single-agent COM701, this is your anti-PVRIG, as maintenance therapy. These are in platinum-sensitive ovarian cancer patients. What specifically about the biology of COM701 kind of gets you excited about the program?

Eran OphirCEO

PVRIG is a checkpoint, but it is a very, very different checkpoint, different from PD1, different from TIGIT, and all the others. I will not go through all the details, but what we have shown extensively that it controls a different stage in the cancer immunity cycle, stem-like memory T cells, and so it really showed activity in our earlier clinical trials in places that typically checkpoints are not working. For example, in the platinum-resistant settings, in last-line patients who failed everything in ovarian cancer, we had responses in COM701 monotherapy in combination. For example, in PD-L1 in ovarian cancer, also in PD-L1-negative ovarian cancer, which historically even PD1 plus TIGIT in combination shows zero response rate. It is different biology that leads to different outcomes, and specifically ovarian cancer was focus indication for us from the beginning.

Eran OphirCEO

The pathway is extremely dominant there, and we are glad to see entering to the clinic that we saw signals, again, monotherapy in combination in the last line ovarian cancer patients. The rationale of the current studies is to try to focus on the patients which are most probable to respond to the biology of COM701. When we initially started in the platinum-resistant, we are now moving earlier into the platinum-sensitive settings. Patient is second, third line that responded to their last line platinum, so they have very low tumor burden. Some of them do not have tumor at all.

Eran OphirCEO

We exclude patient with liver metastasis. They have less exhausted immune system, low tumor burden, and by that, we hope that the signal we have seen in fraction of the patients in the platinum-resistant setting will translate into improving median progression-free survival in this important maintenance settings that have a huge unmet need.

Steven WilleySenior Biotech Analyst

Okay. Maybe you could just kind of remind us a little bit about kind of the adaptive trial design that you're looking to leverage here, and how these answers will either inform or not inform what you choose to do next with this MAIA platform trial.

Eran OphirCEO

The study is focused on second, third line platinum-sensitive patients. These are patients who receive platinum, they respond to the platinum. We take only those who responded to the last line platinum. We exclude patient with liver mets, and then the patients are randomized. 40 patients receive COM701 monotherapy, and 20 patients receive placebo. Because of the no standard of care, we could actually have the luxury of using here a placebo control and compare it to COM701. The goal of this arm of the study, and it is an adaptive trial design- meaning we have now the first arm, which checks COM701 monotherapy, but then we can open more arms very easily for different combination, if you may.

Eran OphirCEO

But the goal of this arm is to show clearly COM701 monotherapy activity versus the internal placebo control. Now, if we see significant monotherapy activity, and if they were improving median PFS for more than six months, we'll discuss maybe a bit later about what we look for, what is clinically meaningful. Then, of course, we could start planning for phase III, but also in parallel, we can now open more arms for combinations, like ADCs or whatever, bevacizumab.

Steven WilleySenior Biotech Analyst

Okay. You talked about kind of the 2-to-1 randomization that this study leverages. I know you've changed, or I guess you revised your assumption around what control arm PFS should look like in this study, and that happened, I guess, after the initiation of enrollment, after the trial had started. Can you just kind of provide some color as to why or how those assumptions changed over time? I guess, what informed that change in viewpoint of what a control arm's going to do?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day